Genolution

Genolution Gross Margin

The Gross Margin of Genolution (225220.KQ) as of Oct 22, 2026 is 37.49 %. In the previous year, Gross Margin was 61.78 % — a change of -39.32% (lower).

Gross Margin

37.49 %

YoY

-39.32%

Last updated:

Gross Margin of Genolution is 2025 37.49 % . Gross Margin of Genolution was 2024 61.78 % . It decreases by -39.32% lower compared to the previous year.

Genolution's gross margin stands at 37.5%, down from 73.3% several years earlier.

The Genolution Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
73.25 KRW
Jan 1, 2019
65.71 KRW
Jan 1, 2020
74.15 KRW
Jan 1, 2021
73.31 KRW
Jan 1, 2022
69.20 KRW
Jan 1, 2023
46.32 KRW
Jan 1, 2024
61.78 KRW
Jan 1, 2025
37.49 KRW
The Genolution Gross Margin history
YEARGross MarginYoY
37.49 %-39.32%
61.78 %+33.38%
46.32 %-33.07%
69.20 %-5.61%
73.31 %-1.13%
74.15 %+12.84%
65.71 %-10.28%
73.25 %-5.54%
77.54 %-5.53%
82.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Gross Margin of Genolution is 37.49 % in 2025.

Gross Margin of Genolution changed from 61.78 % to 37.49 %, representing a -39.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Genolution since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Genolution with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Genolution

All Key Metrics — Genolution